Examples include the addition of a peptide vaccine to the administration of high dose interleukin-2 (IL-2) [13] and the use of a GMCSF-secreting tumor vaccine in combination with CTLA-4 blockade for metastatic prostate cancer [14]. The gene discussed is IL2; the disease is neoplasm.